Clinical Trial Update: Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of response-adapted therapy with copanlisib plus rituximab in previously untreated follicular lymphoma; results were posted in March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Aliqopa (copanlisib)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Follicular Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-03